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Cells from individuals with the recessive cancer-
prone disorder ataxia telangiectasia (A-T) are hypersen-
sitive to ionizing radiation (I-R). ATM (mutated in A-T)
is a protein kinase whose activity is stimulated by I-R.
c-Abl, a nonreceptor tyrosine kinase, interacts with
ATM and is activated by ATM following I-R. Rad51 is a
homologue of bacterial RecA protein required for DNA
recombination and repair. Here we demonstrate that
there is an I-R-induced Rad51 tyrosine phosphorylation,
and this induction is dependent on both ATM and c-Abl.
ATM, c-Abl, and Rad51 can be co-immunoprecipitated
from cell extracts. Consistent with the physical interac-
tion, c-Abl phosphorylates Rad51 in vitro and in vivo. In
assays using purified components, phosphorylation of
Rad51 by c-Abl enhances complex formation between
Rad51 and Rad52, which cooperates with Rad51 in re-
combination and repair. After I-R, an increase in asso-
ciation between Rad51 and Rad52 occurs in wild-type
cells but not in cells with mutations that compromise
ATM or c-Abl. Our data suggest signaling mediated
through ATM, and c-Abl is required for the correct post-
translational modification of Rad51, which is critical for
the assembly of Rad51 repair protein complex following
I-R.
Ataxia telangiectasia (A-T)1 is an autosomal recessive ge-
netic disease characterized by diverse clinical symptoms that
include neuronal degeneration, immune deficiency, gonadal
abnormalities, cancer predisposition, premature aging, and
oculocutaneous telangiectasias (1, 2). Cells from individuals
with A-T are hypersensitive to ionizing radiation (I-R) and
chemicals that cause DNA double-strand breaks (DSB). Upon
I-R, A-T cells exhibit defects in multiple cell cycle checkpoint
functions, including an aberrant p53 response and DNA DSB
repair (1, 3). The DSB repair defect in A-T cells is subtle, but
nevertheless contributes significantly to the radiosensitivity
and chromosomal instability phenotype of these cells (4–6). At
a time when rejoining of I-R-induced DSB is completed in
normal mitotic cells, A-T cells still contain a significant number
of DSBs, which may be converted into chromosomal breaks (7,
8). Additionally, the DSB repair process in A-T cells is error-
prone (9, 10). A-T cells also possess an elevated level of spon-
taneous intrachromosomal recombination (11). In meiosis of
A-T cells, the synaptonemal complexes fail to form at the
pachytene stage, thus aborting gametogenesis (12–14). Little is
known about the molecular basis for the meiotic and DNA DSB
repair defects in A-T cells.
In eukaryotes, DNA DSB can be repaired by either homolo-
gous recombination or nonhomologous end-joining pathways
(15). Homologous recombination is achieved through multiple
enzyme-catalyzed steps that include processing and resection
of the DSB, searching for and pairing of DNA homologs, strand
invasion, DNA synthesis, and finally, resolution of recombina-
tion intermediates (16, 17). Rad51, a eukaryotic homolog of the
bacterial recombinase RecA, is required for recombinational
repair of DSB. In in vitro recombination assays using purified
components, Rad51 catalyzes strand exchange in an ATP-de-
pendent reaction (16, 17). Interactions between yeast Rad51
and other recombination factors including RPA, Rad52, Rad54,
Rad55, and Rad57 have been described (18, 19). Human Rad51
also binds Rad52 (20, 21). Recent biochemical studies have
demonstrated that the strand exchange activity of Rad51 is
stimulated by Rad52, Rad54, and the Rad55zRad57 complex,
indicating that the protein-protein interactions are function-
ally significant (22–26). The results of studies with human
Rad51 and Rad52 suggest that the mechanisms of DSB re-
pair by homologous recombination are conserved in higher
eukaryotes (27).
ATM, the gene mutated in A-T, encodes a 370 kDa protein
that is predominantly nuclear (28–31). It contains a phosphati-
dylinositol kinase domain that is also present in several other
proteins known to function in cellular responses to DNA dam-
age, cell cycle control, and telomere maintenance (32, 33). Upon
activation by DNA damage, the ATM kinase phosphorylates
p53 on serine 15, which results in stabilization of p53 (34, 35).
In addition to modifying p53, ATM is also required for the
activation of the nonreceptor tyrosine kinase c-Abl (36, 37).
ATM binds c-Abl constitutively and may phosphorylate c-Abl
on serine 465, leading to enhanced kinase activity of c-Abl (37).
Whether defective c-Abl activation affects DSB repair and thus
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contributes to the phenotypes of A-T cells remains to be
addressed.
In this study, we tested the hypothesis that the aberrant
DNA repair phenotype of A-T cells is due at least in part to
defective modulation of protein components of the DNA DSB
repair machinery by ATM kinase-mediated signals. We provide
evidence that ATM and c-Abl kinase are required for correct
post-translational modification and assembly of Rad51 protein
complexes.
MATERIALS AND METHODS
Antibodies—The monoclonal anti-ATM antibody 3E8 was made us-
ing GST-ATM-LZP fusion protein as the immunogen. Polyclonal and
monoclonal antibodies against human Rad51 and Rad52 were produced
using HisRad51 and HisRad52 purified from bacteria. The anti-phos-
photyrosine antibodies 4G10 and RC20, anti-b-actin antibody, and anti-
Myc antibody 9E10 were from Upstate Biotechnologies, Transduction
Laboratories, Sigma, and Santa Cruz Biotechnologies, respectively. 8E9
and P6D are monoclonal antibodies that recognize human c-Abl.
Purification of Rad51, Rad52, and c-Abl—Human Rad51 and Rad52
were overexpressed in Escherichia coli. Consecutive chromatographic
steps involving Q-Sepharose, Ni-NTA-agarose (for histidine-tagged
Rad51 only), Affi-blue, hydroxyapatite, and Mono-Q were performed to
purify Rad51, and chromatography on Ni-NTA and Mono-S columns
was used to purify histidine-tagged Rad52. Myc-tagged c-Abl, overex-
pressed in COS-7 cells by transient transfection, was purified by affin-
ity chromatography with the 9E10 antibody immobilized on agarose.
The Myc epitope peptide was used to compete off the c-Abl bound to the
column.
Analysis of Protein Interactions—Cells were lysed in EBC buffer (50
mM Tris, pH 7.6, 120 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 mM
b-mercaptoethanol, 50 mM NaF, and 1 mM Na3VO4) plus protease
inhibitors. Immunoprecipitation was performed as described earlier
(28), using secondary antibodies cross-linked to magnetic beads (Dynal
Inc. Oslo, Norway). To study whether protein complex formation re-
quires DNA, immunoprecipitation was performed in the presence of
ethidium bromide (20 mg/ml), and the immunoprecipitates were treated
with 100 units of DNase I at 37 °C for 1 h. To examine Rad51 tyrosine
phosphorylation, immunoblots containing Rad51 were incubated with
anti-phosphotyrosine antibody and then horseradish peroxidase-conju-
gated secondary antibody. After detection by enhanced chemilumines-
cence (Amersham Pharmacia Biotech), bound antibodies in the blot
were stripped off by incubation in 0.1 M glycine, pH 3.0, for 30 min.
Total Rad51 amounts in the blot were determined with anti-Rad51
antibody. In GST pull-down assays, 1 mg of GST or GST fusion proteins
that had been absorbed on glutathione beads was incubated with target
proteins in EBC buffer for 2 h at 4 °C.
To examine the effects of Rad51 phosphorylation by c-Abl on inter-
action between Rad51 and Rad52, 1 mg of Rad51 was incubated with
affinity purified wild-type or kinase inactive (K290R) c-Abl in kinase
buffer (20 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM MnCl2, and 1 mM
dithiothreitol, 100 mM ATP) at 30 °C for 20 min. After addition of
genistein to inactivate the c-Abl kinase, Rad51 in the kinase reactions
was subjected to immunoprecipitation with a rabbit polyclonal anti-
Rad51 antibody and the anti-phosphotyrosine antibody 4G10. Second-
ary antibodies conjugated with magnetic beads were used to capture the
immune complex. 0.5 mg of Rad52 was then added to the mixture
containing free and antibody-bound Rad51 and incubated at 4 °C for 45
min. Rad51 and Rad52 levels in antibody-bound and -unbound fractions
were determined by immunoblotting with their respective antibodies.
Mapping the Residues of Rad51 Phosphorylated by c-Abl—His6-
Rad51 cDNA was cloned into pCMV vector for expression in mamma-
lian cells. Specific tyrosine residues of Rad51 were mutated to phenyl-
alanine using Quick-changeTM (Stratagene). 8 mg of pSV40-Myc-c-Abl
or -K290R-c-Abl, together with 2 mg of pCMV-His6-Rad51, were used to
transfect COS-7 cells in one 10-cm plate. Two days later, the transfected
cells were lysed in 1% Triton X-100 in EBC buffer containing 1 mM
Na3VO4 and protease inhibitors. His6-Rad51 in the cell lysates was
absorbed to Ni-NTA resin. Proteins bound to the Ni-NTA resin were
eluted with 250 mM imidazole in EBC and were then subjected to
immunoprecipitation with rabbit anti-Rad51 antibody. Tyrosine phos-
phorylation of the immunoprecipitated His6-Rad51 was detected by
immunoblotting with the anti-phosphotyrosine antibody RC20.
RESULTS
I-R-induced Rad51 Tyrosine Phosphorylation Is Dependent
on ATM and c-Abl—We used glutathione beads with glutathi-
one S-transferase (GST)-ATM fusion proteins as the ligand to
bind cellular proteins that may associate with ATM. Rad51 and
c-Abl bound to a GST-ATM fusion protein encompassing the
leucine zipper and proline-rich region (LZP) of ATM (residues
980–1, 437, Fig. 1a, lane 3) but not to GST or a GST-ATM-N (a
fusion protein containing residues 249–523 of ATM) (Fig. 1a,
lanes 2 and 4). Immunoprecipitation was then carried out to
further assess the association between ATM, c-Abl, and Rad51.
Each of these three proteins was detected in immunoprecipita-
tions with anti-ATM, anti-c-Abl or anti-Rad51 antibodies but
not with preimmune IgG (Fig. 1b). Treatment of the immuno-
precipitates with DNase I had no effect on the association
between ATM, c-Abl, and Rad51, indicating that complex for-
mation among these proteins is probably not mediated by DNA
(Fig. 1b). The amount of co-immunoprecipitating proteins did
not change significantly after I-R treatment (data not shown).
Previous studies have demonstrated an ATM-dependent ac-
FIG. 1. a, Rad51 and c-Abl bind the LZP domain of ATM. Left panel,
Coomassie Blue staining of purified GST, GST-ATM-LZP, and GST-
ATM-N after separation by SDS-PAGE. Molecular weight markers are
shown on the left. Right panel, immunoblotting of T24 total cell extracts
(lane 1), T24 cellular proteins pulled down by GST (lane 2), GST-ATM-
LZP (lane 3), and GST-ATM-N (lane 4) with anti-c-Abl and anti-Rad51
antibodies. b, Co-immunoprecipitation of ATM, c-Abl, and Rad51. Raji
cells (5 3 106) were lysed in EBC buffer and subjected to immunopre-
cipitation (IP) using anti-ATM, anti-c-Abl, or anti-Rad51 antibodies.
Proteins in the immunoprecipitates were detected by immunoblotting
(IB) using the indicated antibodies.
















tivation of c-Abl tyrosine kinase following I-R (36, 37).
Prompted by the physical interaction between Rad51 and c-
Abl, we examined if Rad51 is tyrosine phosphorylated before
and after I-R. Extracts prepared from T24 cells before and after
I-R treatment were immunoprecipitated with anti-Rad51 anti-
body followed by sequential immunoblotting with anti-phos-
photyrosine and anti-Rad51 antibodies. Although the levels of
Rad51 did not change, tyrosine phosphorylation of Rad51 in-
creased more than 3-fold following I-R treatment (Fig. 2a).
Tyrosine phosphorylation of Rad51 was also examined in em-
bryonic fibroblasts established from wild-type mice, mice with
nullizygous c-Abl mutation (38), and also from ATM knockout
mice (14). Induction of Rad51 tyrosine phosphorylation after
I-R was seen in wild-type mouse embryonic fibroblasts (MEF),
but not in c-Abl2/2 or ATM2/2 MEF (Fig. 2b). Thus, the in-
duced tyrosine phosphorylation of Rad51 is dependent upon
both ATM and c-Abl. An elevated basal level of Rad51 tyrosine
phosphorylation was detected in c-Abl2/2 MEFs (Fig. 2b). The
reason for this result is unknown, but it could be because of the
presence of a compensatory mechanism that results in an ele-
vated basal level of c-Abl-like activity in c-Abl2/2 MEF, which
also leads to increased tyrosine phosphorylation of other c-Abl
substrates (37).
Whether Rad51 protein can serve as a direct substrate for
c-Abl was tested using purified Rad51, Myc-tagged c-Abl and
kinase-inactive c-Abl (39). Rad51 (Fig. 3a) was phosphorylated
by active c-Abl but not by the kinase-inactive c-Abl. Immuno-
blotting with an anti-phosphotyrosine antibody indicates that
phosphorylation of Rad51 by c-Abl occurred on tyrosine resi-
dues (Fig. 3a). To investigate possible Rad51 phosphorylation
by c-Abl in vivo, Rad51 was expressed together with kinase
inactive or active c-Abl in COS-7 cells. Co-expression of Rad51
with wild-type c-Abl, but not kinase inactive c-Abl, stimulated
Rad51 tyrosine phosphorylation (Fig. 3b). Mutation of Rad51
Tyr315, but not Tyr205, Tyr191, or Tyr54 to phenylalanine abol-
ished Rad51 tyrosine phosphorylation by c-Abl (Fig. 3b). These
results strongly suggest that c-Abl phosphorylates Rad51
Tyr315 in vivo. Interestingly, Rad51 Tyr315 is present in a YXXP
context, a substrate sequence preferred by c-Abl kinase activity
(40), and is a highly conserved residue in Rad51 in all known
species of the animal kingdom.
To determine whether the elevated tyrosine phosphorylation
of Rad51 in c-Abl2/2 MEFs is because of phosphorylation on
Tyr315, wild-type and Y315F Rad51 was expressed in these
cells by transient transfection. The levels of tyrosine phospho-
rylation of wild-type and Y315F Rad51 were similar (Fig. 3c),
suggesting that the majority of Rad51 tyrosine phosphorylation
in c-Abl2/2 MEF does not occur on Tyr315.
Tyrosine Phosphorylation of Rad51 by c-Abl Enhances the
Interaction between Rad51 and Rad52—Genetic and biochem-
ical studies indicate that Rad51 cooperates with Rad52 in re-
combinational DNA repair (18, 22–24, 27). Whether phospho-
rylation of Rad51 by c-Abl modulates its interaction with
human Rad52 was investigated in binding assays employing
purified Rad51 and Rad52 (Fig. 4a). To avoid interference from
possible un-phosphorylated Rad51, anti-phosphotyrosine anti-
body was used to isolate tyrosine phosphorylated Rad51 after
kinase reaction with wild-type c-Abl (Fig. 4b). Approximately
4-fold more Rad52 was associated with tyrosine phosphoryl-
ated Rad51 than with Rad51 treated with K290R c-Abl (Fig.
4b), indicating that tyrosine phosphorylation of Rad51 by c-Abl
enhances its interaction with Rad52 in vitro.
Because I-R induces Rad51 tyrosine phosphorylation in wild-
type cells, but not in ATM2/2 or c-Abl2/2 MEF, we examined
the association between Rad51 and Rad52 in cells with these
distinct genetic backgrounds before and after I-R. Extracts
prepared from mock-treated and irradiated T24, wild-type
MEF, as well as c-Abl2/2 and ATM2/2 MEF were subjected to
immunoprecipitation using anti-Rad51 antibody. The level of
Rad52 in the Rad51 immunoprecipitates was quantitated by
immunoblotting with anti-Rad52 antibody. Significantly more
(.3-fold) Rad52 was co-precipitated after I-R treatment of T24
and wild-type MEF. In contrast, enhanced association of Rad51
and Rad52 was not seen in c-Abl2/2 or ATM2/2 MEF after I-R
(Fig. 5a). I-R did not affect the overall levels of Rad51 and
Rad52 proteins (Fig. 5b). Thus, the I-R-induced association
between Rad51 and Rad52 appears to correlate with the I-R-
FIG. 2. I-R-induced tyrosine phosphorylation of Rad51 in vivo
depends on ATM and c-Abl. a, tyrosine phosphorylation of Rad51 in
T24 cells before and 60 min after I-R. The cell lysates were subjected to
immunoprecipitation (IP) with anti-Rad51 antibody, and immunopre-
cipitates were separated by SDS-PAGE followed by immunoblotting
(IB) with anti-phosphotyrosine antibody. The filter was re-probed with
Rad51 antibody after removal of the anti-phosphotyrosine antibody. b,
tyrosine phosphorylation of Rad51 in wild-type (WT), ATM2/2, and
c-Abl2/2 MEF before and 60 min after I-R. Immunoprecipitation and
immunoblotting were carried out as in panel a.
FIG. 3. a, c-Abl phosphorylates Rad51 in vitro. Left panel, purified
Rad51 stained with Coomassie Blue after SDS-PAGE. Right panel,
tyrosine phosphorylation of Rad51 by c-Abl in vitro. Rad51 was incu-
bated with wild-type (WT) or K290R c-Abl in kinase reactions. Phos-
photyrosine residues, Rad51, and c-Abl were detected by immunoblot-
ting using anti-phosphotyrosine, Rad51, and c-Abl antibodies as
indicated. b, c-Abl phosphorylates Tyr315 of Rad51 in vivo. His6-Rad51,
wild-type, or with the indicated tyrosine to phenylalanine mutations,
were co-expressed with Myc-K290R-c-Abl or Myc-c-Abl in COS-7 cells
and affinity-purified. The relative levels of tyrosine phosphorylated and
total His6-Rad51 were determined by immunoblotting with anti-phos-
photyrosine and anti-Rad51 antibodies, respectively. The expression of
c-Abl in the transfected cells was verified by immunoblotting with
anti-Myc antibody and with anti-b-actin antibody as a control for pro-
tein loading. c, tyrosine phosphorylation of wild-type and Y315F Rad51
in c-Abl2/2 MEF. The wild-type and mutant Rad51 were expressed in
c-Abl2/2 MEF by transient transfection. The relative levels of tyrosine
phosphorylated and total His6-Rad51 were determined as in panel b.
















induced Rad51 tyrosine phosphorylation. Interestingly, there
was an elevated association of Rad51 and Rad52 in c-Abl2/2
MEF before I-R treatment (Fig. 5a), perhaps because of the
increased basal level of Rad51 tyrosine phosphorylation in
these cells.
DISCUSSION
Because A-T cells arrested in the G1 phase of the cell cycle
are radiosensitive, it appears that defective checkpoint control
is not the only cause of radiosensitivity of A-T cells (4–6).
Moreover, the aberrant mitotic recombination and elevated
chromosomal breaks in A-T cells after I-R suggest that ATM
plays a direct role in the repair of DNA DSB (1, 4, 7, 9–11). In
this study, we report that ATM and ATM-mediated signaling
are required for both Rad51 phosphorylation and enhanced
assembly of recombination complexes. Our data support the
hypothesis that defective modulation of repair proteins may
underlie the DNA repair deficiency in A-T cells.
Genetic and biochemical studies have assigned a central role
for Rad51 in homologous recombination. The other recombina-
tion factors, Rad52, Rad54, and Rad55zRad57 stimulate the
strand exchange activity of Rad51 (22–27). This stimulation
likely requires direct interaction between the recombination
proteins because mutant Rad52 lacking the Rad51 binding site
failed to stimulate Rad51-mediated strand exchange (23). Our
study has identified an I-R-induced phosphorylation of Rad51
on tyrosine residues and a concomitant increase in association
between Rad51 and Rad52, which may lead to increased DNA
repair proficiency. The enhanced association of Rad51 and
Rad52 after I-R is likely because of Rad51 tyrosine phospho-
rylation mediated by ATM and c-Abl since the enhanced bind-
ing was also observed after phosphorylation of Rad51 by c-Abl
in vitro. It is not yet known whether phosphorylation of Rad51
affects its binding with other members of the recombination
complex.
While this study was in progress, Yuan et al. (41) reported
that phosphorylation of yeast and human Rad51 by c-Abl in-
hibited the binding of Rad51 to DNA. Furthermore, the strand
exchange activity of yeast Rad51 also decreased upon treat-
ment with c-Abl (41). The authors concluded that c-Abl might
have inhibitory effects on Rad51 activities in vivo. In contrast,
our studies of Rad51zRad52 complex formation in vitro and in
vivo suggest that the ATM and c-Abl-mediated signaling is
likely to promote repair given the biochemical evidence that
Rad51 acts in concert with Rad52 in homologous recombination
(22–24, 27). Future biochemical studies are needed to address
whether in the presence of Rad52, Rad51 would indeed exhibit
higher recombinase activity upon phosphorylation by c-Abl.
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